Pancreatic Cancer Research

ResearcherBaylor College of MedicineActive in the last 2 years

William E Fisher

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4819-4409; OpenAlex author ID A5125468676; NIH RePORTER profile ID 1869434. Sources: ClinicalTrials.gov.

Their work

Papers
5
Trials
2 (principal investigator on 2)
Grants
1
Labs led
1
Collaborators
32
Papers, trials and grants by year

2011: 1 trial · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 trial · 2022: none · 2023: none · 2024: 1 grant · 2025: none · 2026: 5 papers

Papers 5

  1. Missed Opportunities for Multimodality Therapy in Resectable Pancreatic Cancer: National Disparities and Consequences for Survival. Co-author DOI 10.1002/jso.70408↗
  2. Diabetes secondary to chronic pancreatitis and pancreatic cancer: Observations from the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancrea… Co-author DOI 10.1016/j.pan.2026.04.001↗
  3. Towards early detection of pancreatic cancer: The current status of cohort studies by the Diabetes-Pancreatic Ductal AdenoCarcinoma Working Group. Co-author DOI 10.1016/j.pan.2026.04.020↗
  4. Risk of Pancreatic Cancer in Glycemically Defined New-Onset Diabetes: A Prospective Cohort Study. Co-author DOI 10.1053/j.gastro.2025.06.025↗
  5. Heuriskance: a novel paradigm for systematic earlier detection of sporadic pancreatic cancer. Co-author DOI 10.1093/jnci/djaf291↗

Trials 2

  1. Early Detection Initiative for Pancreatic Cancer Principal investigator NCT04662879↗
  2. Pancreas Resection With and Without Drains Principal investigator NCT01441492↗

Grants 1

  1. DYSBIOTIC MICROBIOME IN PANCREATITIS, DIABETES, AND PANCREATIC CANCER U01DK108326↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anirban Maitra · 3 shared papers, 1 shared trial, 2021–2026 · strength 1.00
  2. Suresh T. Chari · 3 shared papers, 1 shared trial, 2021–2026 · strength 1.00
  3. Ziding Feng · 2 shared papers, 1 shared trial, 2021–2026 · strength 0.76
  4. Phil A. Hart · 3 shared papers, 2026 · strength 0.71
  5. Barbara J. Kenner · 2 shared papers, 2026 · strength 0.52
  6. Ying‐Qi Zhao · 2 shared papers, 2026 · strength 0.52
  7. Bechien U. Wu · 2 shared papers, 2026 · strength 0.52
  8. Lynn McCormick Matrisian · 2 shared papers, 2026 · strength 0.52
  9. Christopher E Forsmark · 2 shared papers, 2026 · strength 0.49
  10. Evan L Fogel · 2 shared papers, 2026 · strength 0.49
  11. Stephen Jacob Pandol · 2 shared papers, 2026 · strength 0.49
  12. Walter Gwang-Up Park · 2 shared papers, 2026 · strength 0.49
  13. Bechien Wu · 1 shared paper, 1 shared trial, 2021–2026 · strength 0.48
  14. Jo Ann Rinaudo · 2 shared papers, 2026 · strength 0.46
  15. Santhi Swaroop Vege · 2 shared papers, 2026 · strength 0.46
  16. Ernest Ramsay Camp · 1 shared paper, 2026 · strength 0.33
  17. Eric Jay Silberfein · 1 shared paper, 2026 · strength 0.33
  18. Derek J. Erstad · 1 shared paper, 2026 · strength 0.33
  19. John C. Johnson · 1 shared paper, 2026 · strength 0.33
  20. George Van Buren · 1 shared paper, 2026 · strength 0.33
  21. Avinash R. Kambadakone · 1 shared paper, 2026 · strength 0.30
  22. Yogish C. Kudva · 1 shared paper, 2026 · strength 0.24
  23. Frederico G. S. Toledo · 1 shared paper, 2026 · strength 0.24
  24. Mark Goodarzi · 1 shared paper, 2026 · strength 0.24
  25. Melena D. Bellin · 1 shared paper, 2026 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.